Update shared on 30 Oct 2025
Galenica's analyst price target remains unchanged at CHF 85.50. Analysts cite minimal revisions to growth and margin assumptions since the previous update.
What's in the News
- Galenica is piloting a new pharmacy concept in Zurich’s Glattzentrum, featuring enhanced consultations, a modernized store design, and integrated digital support (Key Developments).
- The revamped Amavita pharmacy will open on 25 October 2025 and will offer express checkouts, private consultation rooms, and semi-private areas for collaborative service discussions (Key Developments).
- Galenica has reconfirmed its 2025 financial guidance, expecting consolidated net sales growth between 3% and 5%, and an EBIT increase of 7% to 9% because of strong first-half performance and positive one-time effects (Key Developments).
- The company aims to at least maintain last year’s dividend level for 2025 (Key Developments).
- Galenica continues to invest in integrating digital and in-store pharmacy offerings. This approach responds to the trend that 80% of customers seek information online before visiting a pharmacy (Key Developments).
Valuation Changes
- Consensus Analyst Price Target remains unchanged at CHF 85.50.
- Discount Rate is unchanged at 3.82%.
- Revenue Growth forecast has decreased marginally from 3.61% to 3.61%.
- Net Profit Margin has risen slightly, from 4.70% to 4.70%.
- Future P/E multiple has declined marginally from 22.72x to 22.71x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.